



Multimeric Biotherapeutics, Inc.
(“MultimericBio”)
“Unlocking the potential of the TNF SuperFamily Ligands”

Multimeric Biotherapeutics, Inc. receives an NIH grant to develop a vaccine against nicotine as an aid to smoking cessation

April 24, 2010, La Jolla, CA – Multimeric Biotherapeutics, Inc. (“MultimericBio”) announced that it has been awarded a two-year Innovation grant from the National Institute on Drug Abuse (NIDA) at the NIH to develop a next generation vaccine against nicotine and eventually other drugs of abuse. This will be the first test of the company’s Precision Immunization™ vaccine strategy, a revolutionary technology for eliciting strong, highly targeted antibody responses.

Cigarette smoking is the leading preventable cause of death in the U.S. and accounts for about 1 of every 5 deaths (438,000 people) each year. Vaccines against nicotine are designed to generate antibodies that sequester inhaled nicotine in the blood, thereby preventing it from crossing into the brain and re-enforcing the nicotine habit. When combined with an abstinence program and counseling, a nicotine vaccine is anticipated to help smokers eliminate cigarettes from their lives.

If the early testing is successful, the company hopes to engage a Pharma partner to bring its new nicotine vaccine to patients. Two other companies developing nicotine vaccines have each found a major Pharma partner and entered into deals potentially worth \$500 million in each case. Consequently, the development of an effective nicotine vaccine would add significant value for MultimericBio’s investors.

About Precision Immunization™

Precision Immunization™ is MultimericBio’s proprietary platform technology for eliciting highly focused antibody responses. Whereas standard immunizations raise both correctly targeted and ineffective off-target antibodies, Precision Immunization™ is designed to focus the antibody response exactly on the selected target. As such, Precision Immunization™ lies in the middle ground between classical vaccination and the passive administration of specific monoclonal antibodies (e.g., Rituxan®, Herceptin®, Avastin®, Xolair®, and others). Currently, MultimericBio is performing preclinical testing of Precision Immunization™ for a variety of uses.

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is a privately held, early-stage biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. Its core, patented technology is being used to create next-generation vaccines and tumor immunotherapies. MultimericBio has offices in La Jolla, CA, and laboratories in Carlsbad, CA, both in the San Diego area. More information is available at www.multimericbio.com . Contact us at info@multimericbio.com

About NIDA

The National Institute on Drug Abuse is dedicated to the science of drug abuse and addiction. One of its primary goals is the development of medications to treat addiction, including an effective nicotine vaccine. For a perspective on NIDA’s interest in nicotine vaccines, see the comments of Dr. Nora D. Volkow, NIDA Director, at <http://www.nida.nih.gov/about/welcome/messagenicvax.html> .